Does young blood hold the fountain of youth? Can transfusions of blood from younger donors reverse or slow down the aging process in an older recipient?
Dear parents, customers of Biohellenika
We receive phone calls from parents who cryopreserved their children's tooth stem cells at Biohellenika’s laboratories and their children have reached the age of 18. You are asking us if a new contract needs to be signed by your children, because they have reached the age of majority. According to the contract that parents have signed, after the child turns 18 the ownership of the contract is transferred entirely to the child and no new contract needs to be signed. The contract is valid for 20 years, from the day the stem cells are cryopreserved and will be renewed by the child himself at the end of 20 year storage.
On behalf of Biohellenika AE
Dr K Kouzi-Koliakou MD, PhD
Medical Director of Biohellenika
Аn optimized, simplified and clinically approved culture system to produce, in large scale, dendritic cells capable of priming specific T cells
Eleni Gounari a,b,*, Nikolaos Tsagias a, Angelos Daniilidis c, Kokkona Kouzi a,d, George Koliakos a,b
a Biohellenika Biotechnology Company, Thessaloniki, Greece
b Department of Biochemistry, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
c 2nd Department of Obstetrics and Gynecology, Hippokratio General Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece d Department of Histology Embryology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece A
Keywords: Dendritic cells Hematopoietic stem cells Specific T-cells Colorectal cancer (CRC) Cancer immunotherapy
A B S T R A C T
Cancer immunotherapy using dendritic cells (DCs) able to induce specific immune responses to naïve T lymphocytes raises great research interest. However, the extremely complex and expensive methods used to produce DCs, combined with the limited number of autologous DCs in the circulation make any application almost impossible. Aim of the study is the development of an optimized and simplified system to easily produce in large scale cord blood-derived DCs, loaded with common tumor antigens, capable of promoting controlled Th1 immunoresponses following clinically approved maturation with vaccines. CD34+cells cultured in the presence of a cytokine cocktail in miniPERM® bioreactors and the generated DCs were matured using anti-flu vaccines. Autologous T cells plated with DCs pulsed with overlapping peptides CEA and WT1 for multiple stimulations. 200 billion of myeloid DCs were produced and matured in just 8 h in bioreactors, presenting an increased expression of the co-stimulatory molecules and also high levels of Th1 related cytokines. Upon just the 2nd stimulation, the T cells exhibited specificity following stimulation with the CEA/WT1 peptides and strong cytotoxic capacity in co-culture with a colorectal cancer (CRC)-cell line. The high produced doses of DCs, easily maturated with clinically approved agents, and capable of priming specific T cells, could potentially strengthen the further progress in DCs-mediated cancer immunotherapy field.
Differentiation, 125 (2022) 54–61
2022 Update: How many clinical trials use cord blood or cord tissue? August 2022 Frances Verter, PhD
Source # Cumulative Trials Advanced Cell Therapy through end of 2021 # Recruiting Trials Any Therapy June 2022 Cord Blood 276 110 Cord Tissue 464 n/a Other Perinatal 151 n/a
From the beginning of advanced cell therapy with cord blood until the end of 2021, 276 cord blood clinical trials have been registered worldwide. We checked the status of these trials in June 2022 and found that 110 cord blood trials, both advanced therapy and traditional transplants, are recruiting at 281 locations. We have updated our portal of recruiting cord blood trials to enable patients and their families to look up these recruiting trials by the diagnosis treated. We have also updated our statistics on advanced cell therapy with cord tissue, as well as other perinatal sources such as the placenta and amniotic membrane. Cumulatively through the end of 2021, there have been 464 trials with cord tissue alone and 151 trials with other perinatal tissues and combinations of perinatal tissues. Annual numbers of trials with cord tissue have grown more than four-fold over the time span from 2015 to 2020. In 2021 there were 30 trials registered for cord blood and 96 for cord tissue. We have not updated our portal of recruiting cord tissue trials because it has simply become too time consuming to check the status of so many trials. To learn more about cord blood banking, visit Parent's Guide to Cord Blood Foundation at https://parentsguidecordblood.org/en/news/2022-update-how-many-clinical-trials-use-cord-blood-or-cord-tissue
Recently a new parer was published by the R&D Department of Biohellenika, usind the cord blood to develop autologous immunotherapies
Аn optimized, simplified and clinically approved culture system to produce, in large scale, dendritic cells capable of priming specific T cells
Eleni Gounari a,b,*, Nikolaos Tsagias a, Angelos Daniilidis c, Kokkona Kouzi a,d, George Koliakos a,b
Differentiation, 125 (2022): 54–61
a Biohellenika Biotechnology Company, Thessaloniki, Greece
b Department of Biochemistry, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
c 2nd Department of Obstetrics and Gynecology, Hippokratio General Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
d Department of Histology Embryology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
Keywords: Dendritic cells Hematopoietic stem cells Specific T-cells Colorectal cancer (CRC) Cancer immunotherapy
A B S T R A C T
Cancer immunotherapy using dendritic cells (DCs) able to induce specific immune responses to naïve T lymphocytes raises great research interest. However, the extremely complex and expensive methods used to produce DCs, combined with the limited number of autologous DCs in the circulation make any application almost impossible. Aim of the study is the development of an optimized and simplified system to easily produce in large scale cord blood-derived DCs, loaded with common tumor antigens, capable of promoting controlled Th1 immunoresponses following clinically approved maturation with vaccines. CD34+cells cultured in the presence of a cytokine cocktail in miniPERM® bioreactors and the generated DCs were matured using anti-flu vaccines. Autologous T cells plated with DCs pulsed with overlapping peptides CEA and WT1 for multiple stimulations. 200 billion of myeloid DCs were produced and matured in just 8 h in bioreactors, presenting an increased expression of the co-stimulatory molecules and also high levels of Th1 related cytokines. Upon just the 2nd stimulation, the T cells exhibited specificity following stimulation with the CEA/WT1 peptides and strong cytotoxic capacity in co-culture with a colorectal cancer (CRC)-cell line. The high produced doses of DCs, easily maturated with clinically approved agents, and capable of priming specific T cells, could potentially strengthen the further progress in DCs-mediated cancer immunotherapy field.
Stem Cells Bank Biohellenika - Web design Hexabit - W3C - Pagespeed